Solid Biosciences Inc. (SLDB)
Nasdaq · Healthcare · Biotechnology
$7.06+3.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $757M
- 52-week range
- $3.79 – $11.45
- 52-week change
- +24.09%
- EPS (trailing)
- −$1.89
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 2, 2026
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.
Headquarters: Charlestown, United States · 121 employees · solidbio.com